Century Therapeutics Net Income From Continuing Ops Over Time
| IPSC Stock | USD 2.05 0.31 13.14% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Century Therapeutics Performance and Century Therapeutics Correlation. Will Biotechnology sector continue expanding? Could Century diversify its offerings? Factors like these will boost the valuation of Century Therapeutics. Market participants price Century higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Century Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.32) | Revenue Per Share | Quarterly Revenue Growth 126.677 | Return On Assets | Return On Equity |
Investors evaluate Century Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Century Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Century Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Century Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Century Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Century Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income From Continuing Ops Analysis
Compare Century Therapeutics and related stocks such as Coeptis Therapeutics, Medicus Pharma, and Cue Biopharma Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COEP | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (13.4 M) | (37.6 M) | (20.2 M) | (10.9 M) | (9.8 M) | (10.3 M) |
| MDCX | (693.8 K) | (3.4 K) | (3.4 K) | (3.4 K) | (3.4 K) | (3.4 K) | (5.8 K) | (138.9 K) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (1.7 M) | (5.3 M) | (11.2 M) | (10 M) | (9.5 M) |
| CUE | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (7.7 M) | (23.2 M) | (39 M) | (36.7 M) | (44.8 M) | (44.2 M) | (53 M) | (50.7 M) | (40.7 M) | (36.6 M) | (38.4 M) |
| EQ | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (13.3 M) | (25.6 M) | (29.8 M) | (39.1 M) | (62.4 M) | (8.2 M) | (8.1 M) | (7.3 M) | (7.6 M) |
| SNTI | (19.9 M) | (19.9 M) | (19.9 M) | (19.9 M) | (19.9 M) | (19.9 M) | (19.9 M) | (19.9 M) | (19.9 M) | (19.9 M) | (19.9 M) | (55.3 M) | (58.2 M) | (88.3 M) | (52.8 M) | (47.5 M) | (49.9 M) |
| TELO | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (854.1 K) | (13.1 M) | (16.5 M) | (16.5 M) | (14.9 M) | (14.1 M) |
| OSTX | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (6.3 M) | (7.8 M) | (8.9 M) | (8 M) | (8.4 M) |
| KPTI | (33.9 M) | (33.9 M) | (33.9 M) | (33.9 M) | (75.8 M) | (118.2 M) | (109.6 M) | (129 M) | (178.4 M) | (199.6 M) | (196.3 M) | (124.1 M) | (165.3 M) | (139.8 M) | (76.4 M) | (68.8 M) | (72.2 M) |
| OTLK | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (48.7 M) | (53.3 M) | (38.8 M) | (30.1 M) | (34.5 M) | (35.2 M) | (53.2 M) | (66.1 M) | (59 M) | (75.4 M) | (62.4 M) | (56.2 M) | (59 M) |
| GNTA | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (5.6 M) | (5.5 M) | (8.5 M) | (11.6 M) | (8.9 M) | (8 M) | (8.4 M) |
Century Therapeutics and related stocks such as Coeptis Therapeutics, Medicus Pharma, and Cue Biopharma Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Century Therapeutics | IPSC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 25 North 38th |
| Exchange | NASDAQ Exchange |
USD 2.05
Check out Century Therapeutics Performance and Century Therapeutics Correlation. For information on how to trade Century Stock refer to our How to Trade Century Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Century Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.